Sarepta shares tumble on second patient death after gene therapy treatment

Sarepta Therapeutics' shares plummeted 34% after the company reported a second patient death linked to acute liver failure following treatment with its Elevidys gene therapy for Duchenne muscular dystrophy. The company has suspended Elevidys shipments for non-ambulatory patients and is working with regulators to evaluate an enhanced immunosuppressive regimen, while Roche, its commercialization partner outside the U.S., has paused dosing for the same patient group. Piper Sandler downgraded Sarepta to 'neutral' and significantly cut its price target, citing increased risk for non-ambulatory patients and the need for further safety data.

Analysis

Sarepta Therapeutics (SRPT) experienced a significant 34% premarket share price decline following the disclosure of a second patient death due to acute liver failure after receiving its Duchenne muscular dystrophy gene therapy, Elevidys. This fatality, occurring within three months of a similar incident and involving a non-ambulatory patient, has prompted Sarepta to temporarily suspend Elevidys shipments for this patient subgroup while it investigates an enhanced immunosuppressive regimen with regulatory bodies. Concurrently, Roche, Sarepta's ex-U.S. commercialization partner, has also paused dosing for non-ambulatory patients. The developments have triggered a sharp negative response from analysts, with Piper Sandler downgrading SRPT to 'neutral' from 'overweight' and drastically cutting its price target to $36 from $70, citing a near certainty of high risk for non-ambulatory patients and the likely requirement for new safety data before broader commercial approval. Jefferies analysts also expressed concerns over Elevidys' sales outlook, given it is the sole FDA-approved gene therapy for Duchenne in patients aged four and above. While liver damage is a recognized risk for adeno-associated viral vector-based gene therapies like Elevidys, these repeated incidents raise substantial questions about the therapy's benefit-risk profile, particularly for the non-ambulatory population, and its overall market trajectory, reflected in the extremely negative sentiment score of -0.85.

Key Decisions for Investors

• Investors should acknowledge the substantially increased risk profile and negative sentiment surrounding Sarepta Therapeutics, underscored by the 34% share price plunge and the per-ticker sentiment score of -0.9 for SRPT.
• Carefully monitor all forthcoming safety data releases, regulatory communications regarding the enhanced immunosuppressive regimen for Elevidys, and any decisions concerning its application in non-ambulatory patients, as these will be critical for assessing the therapy's viability and Sarepta's valuation.
• Re-evaluate exposure to SRPT in light of significant analyst downgrades, such as Piper Sandler's revision to 'neutral' with a price target slashed to $36 from $70, reflecting heightened uncertainty over Elevidys' commercial prospects and potential revenue impact.